9家支持的Nanyang Biologics将通过15亿美元的SPAC合并上市;股价上涨

2025-10-02 20:10

Nanyang Biologics, backed by The9 Limited (NASDAQ:NCTY), will merge with SPAC RF Acquisition Corp II (NASDAQ:RFAI) to become publicly listed on Nasdaq.
The combined company will trade under the reserved ticker symbol “NYB” after closing.
The deal values NYB at a $1.5B pre-transaction equity value.
NYB shareholders, including The9, will roll over 100% of their equity and retain majority ownership and board control.
The transaction has board approval and is expected to close in Q1 or Q2 2026.
NYB will leverage its AI platform to speed up drug discovery and develop natural ingredient-based therapies.
NCTY shares up 13% premarket on Thursday.
Source: Press release

More on The9 Limited, RF Acquisition Corp II